new PPRS and other pharmaceutical cost-containment measures in the United Kingdom
Read Online

new PPRS and other pharmaceutical cost-containment measures in the United Kingdom

  • 901 Want to read
  • ·
  • 23 Currently reading

Published by Decision Resources in Waltham, MA .
Written in English



  • Great Britain.


  • Drugs -- Prices -- Great Britain.,
  • Pharmaceutical industry -- Great Britain.,
  • Pharmaceutical policy -- Great Britain.,
  • Market surveys -- Great Britain.

Book details:

Edition Notes

StatementDonald Macarthur.
SeriesDR reports
ContributionsDecision Resources, Inc.
LC ClassificationsHD9667.4 .M33 1995
The Physical Object
Paginationxii, 128 leaves ;
Number of Pages128
ID Numbers
Open LibraryOL459060M
LC Control Number98176617

Download new PPRS and other pharmaceutical cost-containment measures in the United Kingdom


  This document details the agreement between the Department of Health and the Association of the British Pharmaceutical Industry (ABPI) on the outline terms of the new scheme will Author: Department of Health And Social Care. A vast majority of the EU countries are witnessing a rise in the share of public pharmaceutical spending in the total drugs expenditure. This urges governments to adopt cost containment measures. Manufacturers are free to set prices of orphan drugs in the United Kingdom, although the Pharmaceutical Price Regulation Scheme (which regulates industry . 30 A.H. Rietveld and F.M. Haaijer-Ruskamp / Policy options for cost containment of pharmaceuticals is thought to indicate better quality and, vice versa, a low price (as in the case of generics.

The headlines of the Pharmaceutical Pricing Regulatory Scheme (PPRS) were published last Wednesday. This is a voluntary scheme which regulates the prices for branded pharmaceutical medicines across primary and secondary care in the UK, but does not cover generic medicines. In launching the scheme the Department of Health said. Copayments were the most commonly used cost-containment measure, though their use and amount varied for those with certain conditions, most often chronic diseases (in 17 countries), and by socio. The Pharmaceutical Price Regulation Scheme (the scheme) is a non-contractual voluntary scheme effective from the termination of the Pharmaceutical Price Regulation Scheme (the PPRS) on 31 December The parties to the scheme are the Department of Health (the Department), acting on behalf of the UK Government. It is aided in this process by some of Europe's most conservative and const-conscious prescribers, not to mention some its least demanding patients. Only 35% of consultations with general practitioner end with a prescription. Only 14% of drug costs are due to innovative medicines launched in the previous five years. At £, medicines consumption per capita is 75% that of Germany's and only.

  PPRS, to regulate the cost of brand-name the accord that took effect January , the bill for branded medicines was to remain flat for two years and then to . Research Article Health Affairs Vol No.4 Health Care Cost Containment Strategies Used In Four Other High-Income Countries Hold Lessons For The United States. Transparency Directive. The EU has created a common procedural framework through the adoption of the so-called Transparency Directive (Council Directive 89//EEC) to ensure that national pricing and reimbursement decisions are made in a transparent manner and do not disrupt the operation of the Internal Market.. Commission initiatives. The European Commission launched a number of initiatives.   The current version of this Pharmaceutical Price Regulation Scheme (PPRS) has been in place since and is to last until The rate of return is in the range %; for individual firms it varies `having regard to the scale and nature of the company's relevant investments and activities and associated long-term risks'.